Italy Vaccines Market Overview, 2028

The increasing numbers of vaccine administrations are associated with increased reports of adverse vaccine reactions. Vaccines are a vital tool in safeguarding public health and preventing the spread of infectious diseases. Their necessity cannot be overstated, as they play a crucial role in protecting individuals and communities from potentially life-threatening illnesses. Vaccines work by stimulating the immune system to produce antibodies against specific pathogens, such as bacteria or viruses, without causing the disease itself. This means that when a vaccinated person encounters the actual pathogen, their immune system is already prepared to mount a swift and effective defense, reducing the severity of the illness or preventing it altogether. Italy, like many countries around the world, has implemented a comprehensive vaccine usage strategy to protect its population from infectious diseases. Vaccination in Italy is considered a fundamental component of public health policy. The country follows a national vaccination schedule that outlines the recommended vaccines for individuals of different age groups. This schedule includes vaccines for diseases such as measles, mumps, rubella, hepatitis, and influenza, among others. The Italian government, in coordination with the Ministry of Health and the Italian Medicines Agency (AIFA), has been actively engaged in vaccine distribution and administration. Local health authorities, regional governments, and municipalities have played pivotal roles in executing vaccination campaigns. Furthermore, Italy has benefited from partnerships with pharmaceutical companies like Pfizer, Moderna, and AstraZeneca, which have supplied vaccines to the country. The government has also provided financial incentives to healthcare professionals involved in the vaccination process, ensuring a robust healthcare workforce.

According to the research report, “Italy Vaccine Market Overview, 2028” published by Bonafide Research, the Italy Vaccine market is anticipated to grow with more than 7% CAGR from 2023 to 2028. Italy has a highly developed healthcare infrastructure, which includes a network of hospitals, clinics, and vaccination centers. This infrastructure allows for efficient vaccine distribution and administration, making it easier for the population to access vaccines. There has been a notable increase in public awareness regarding the importance of vaccination for preventing infectious diseases. This is partly due to public health campaigns and educational initiatives that promote vaccination as a vital tool for individual and community health. Italy’s actively participates in global vaccine initiatives and collaborations, contributing to the expansion of vaccine access and distribution both domestically and internationally.

On the basis of different types of technology the vaccines are produced which depends on the pathogen (virus or bacteria) that is being targeted to generate a vaccine. This vaccine includes Conjugated Vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, and Toxoid vaccines. In Italy, as of 2022, the landscape of the vaccine market is marked by the dominance of conjugated vaccines, which have emerged as the frontrunners in safeguarding public health. These vaccines, known for their efficacy and safety, have gained prominence in Italy's immunization programs, particularly for preventing diseases like pneumococcal infections and meningitis. Their success can be attributed to the conjugation process, which enhances the body's immune response and provides lasting protection. Following closely behind are live attenuated vaccines, which have also found a significant place in Italy's vaccine market. Live attenuated vaccines, such as those for measles, mumps, and rubella (MMR), have been crucial in controlling and preventing the spread of contagious diseases. Their ability to mimic natural infections without causing severe illness has made them indispensable tools in public health campaigns. Additionally, recombinant vaccines have made their mark in Italy's vaccine market, further diversifying the immunization portfolio. These innovative vaccines, created through genetic engineering techniques, are used to combat diseases like hepatitis B. They are valued for their precision and safety, making them an attractive option for healthcare providers and patients alike. This evolving landscape in Italy's vaccine market reflects a commitment to proactive healthcare measures and the adoption of advanced technologies to protect the population from a range of infectious diseases. It underscores the importance of a well-rounded immunization strategy that combines tried-and-true methods with innovative approaches to ensure the health and well-being of the Italian population in 2022 and beyond.

By the Type of Vaccines, the market is segmented into Multivalent and Monovalent Vaccines. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes/serogroups in combination (multivalent or polyvalent vaccines). Multivalent vaccines and monovalent vaccines each hold distinct importance in the field of immunization, catering to different aspects of disease prevention. While multivalent vaccines are more commonly used in many vaccination programs, both types play crucial roles in safeguarding public health. Multivalent vaccines are designed to protect against multiple diseases or strains within a single vaccine shot. They offer the advantage of convenience, reducing the number of vaccinations individuals need to receive. These vaccines simplify vaccination schedules, improve compliance, and help control the spread of multiple diseases efficiently. On the other hand, monovalent vaccines are specifically tailored to protect against a single disease or pathogen. They are valuable when dealing with diseases where the pathogen exhibits significant variations, or when targeting a specific health threat, such as a new emerging infectious disease or a disease with a complex structure. Monovalent vaccines offer precision in immunization, ensuring focused protection against a particular threat. The choice between multivalent and monovalent vaccines depends on several factors, including the epidemiology of the disease, the population's susceptibility, and the availability of effective vaccines. Both types contribute to the success of vaccination programs and the reduction of disease burden. Multivalent vaccines provide broad protection, while monovalent vaccines offer tailored defense when needed.

Considered in this report:
• Geography: Italy
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028



Aspects covered in this report:
• Italy Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.